tetano
Editor, Senior Moderator
Cureus
. 2022 Sep 23;14(9):e29491.
doi: 10.7759/cureus.29491. eCollection 2022 Sep.
A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
Louise Asleson[SUP] 1 [/SUP], Mohammed Zalabani[SUP] 1 [/SUP], Mohammad Selim[SUP] 1 [/SUP]
Affiliations
Abstract
Renal vein thrombosis (RVT) is a rare form of deep venous thrombosis. It usually involves one or both renal veins and one of their branches. Most cases were reported in patients with nephrotic syndrome or inherited hypercoagulability syndromes. RVT can present with flank pain, hematuria, and acute kidney injury but can also present asymptomatically and be incidentally discovered on abdominal or renal imaging. The management of RVT is usually with warfarin for at least six to 12 months and periodically is continued if the patient is in the nephrotic range. Direct-acting oral anticoagulants (DOACs) have not been well studied in cases of RVT, especially in patients with coronavirus disease 2019 (COVID-19). We present a case of RVT in the setting of COVID-19 that was treated successfully with a DOAC, rivaroxaban, with complete resolution of the thrombus.
Keywords: covid-19; covid-19 associated coagulopathy; direct oral anticoagulants (doac); renal vein thrombosis; rvt.
. 2022 Sep 23;14(9):e29491.
doi: 10.7759/cureus.29491. eCollection 2022 Sep.
A Case of Renal Vein Thrombosis Associated With COVID-19 Treated With Rivaroxaban
Louise Asleson[SUP] 1 [/SUP], Mohammed Zalabani[SUP] 1 [/SUP], Mohammad Selim[SUP] 1 [/SUP]
Affiliations
- PMID: 36299976
- PMCID: PMC9588280
- DOI: 10.7759/cureus.29491
Abstract
Renal vein thrombosis (RVT) is a rare form of deep venous thrombosis. It usually involves one or both renal veins and one of their branches. Most cases were reported in patients with nephrotic syndrome or inherited hypercoagulability syndromes. RVT can present with flank pain, hematuria, and acute kidney injury but can also present asymptomatically and be incidentally discovered on abdominal or renal imaging. The management of RVT is usually with warfarin for at least six to 12 months and periodically is continued if the patient is in the nephrotic range. Direct-acting oral anticoagulants (DOACs) have not been well studied in cases of RVT, especially in patients with coronavirus disease 2019 (COVID-19). We present a case of RVT in the setting of COVID-19 that was treated successfully with a DOAC, rivaroxaban, with complete resolution of the thrombus.
Keywords: covid-19; covid-19 associated coagulopathy; direct oral anticoagulants (doac); renal vein thrombosis; rvt.